ALNY
Alnylam Pharmaceuticals Inc
NASDAQ: ALNY · HEALTHCARE · BIOTECHNOLOGY
$301.19
-0.30% today
Updated 2026-04-29
Market cap
$40.19B
P/E ratio
129.82
P/S ratio
10.82x
EPS (TTM)
$2.32
Dividend yield
—
52W range
$246 – $496
Volume
1.1M
Alnylam Pharmaceuticals Inc (ALNY) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
7 of 8
Last 8 quarters
Avg EPS surprise
+56.7%
Last 4 quarters
Revenue YoY growth
+84.9%
Most recent quarter
EPS YoY growth
+1983.3%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+3.5%
Last 3 reports
Positive reaction rate
33%
1 of 3 quarters
Largest single-day move
+18.2%
2025-07-31
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-02-12 | $1.25 | +0.8% | $322.28 | $314.40 | -2.4% |
| 2025-10-30 | $2.90 | +101.4% | $481.59 | $456.04 | -5.3% |
| 2025-07-31 | $-0.51 | +27.1% | $339.80 | $401.80 | +18.2% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $1.24 | $1.25 | +0.8% | $1.10B | +84.9% |
| 2025-09-30 | $1.44 | $2.90 | +101.4% | $1.25B | +149.3% |
| 2025-06-30 | $-0.70 | $-0.51 | +27.1% | $773.69M | +17.3% |
| 2025-03-31 | $-0.37 | $-0.01 | +97.3% | $594.19M | +20.2% |
| 2024-12-31 | $-0.14 | $0.06 | +142.9% | $593.17M | +34.9% |
| 2024-09-30 | $-0.39 | $-0.50 | -28.2% | $500.92M | -33.3% |
| 2024-06-30 | $-1.08 | $-0.13 | +88.0% | $659.83M | +107.0% |
| 2024-03-31 | $-1.18 | $-0.52 | +55.9% | $494.33M | +54.8% |
| 2023-12-31 | $-1.32 | $-1.10 | +16.7% | $439.72M | — |
| 2023-09-30 | $-1.34 | $1.15 | +185.8% | $750.53M | — |
| 2023-06-30 | $-1.37 | $-2.21 | -61.3% | $318.75M | — |
| 2023-03-31 | $-1.77 | $-1.40 | +20.9% | $319.29M | — |
Analyst EPS and revenue estimates for upcoming years
| Period | EPS estimate | Revenue estimate | Revenue growth | Analysts | Confidence |
|---|---|---|---|---|---|
| 2026 (E) | $7.46 | $4.5B | +22.6% | 28 | high |
| 2027 (E) | $11.16 | $6.0B | +30.8% | 28 | high |
| 2029 (E) | $19.30 | $9.7B | +26.1% | 28 | medium |
| 2030 (E) | $23.90 | $11.9B | +23.8% | 28 | medium |
Frequently asked questions
Has Alnylam Pharmaceuticals Inc beaten earnings estimates?
Alnylam Pharmaceuticals Inc has beaten Wall Street EPS estimates in 7 of its last 8 quarterly reports, with an average EPS surprise of +56.7% over the last 4 quarters.
How does ALNY stock react to earnings?
ALNY stock has moved an average of +3.5% in the trading day following earnings over its last 3 reports, with positive reactions in 33% of those quarters.
What is Alnylam Pharmaceuticals Inc's revenue growth rate?
Alnylam Pharmaceuticals Inc reported year-over-year revenue growth of +84.9% in its most recent quarter, with EPS growing +1983.3% year-over-year.
What is the expected EPS for ALNY in 2026?
Analysts expect Alnylam Pharmaceuticals Inc to report EPS of $7.46 for fiscal year 2026, on revenue of $4.5B, based on estimates from 28 analysts.